ST GALLEN, SWITZERLAND—The controversy about the effectiveness of mammographic screening was aired at the 2013 conference on “Primary Therapy of Early Breast Cancer” by Dr Donald Berry of the University of Texas M D Anderson Cancer Center in Houston. While …
Oncology
ORLANDO, FLORIDA—Patients with low-risk prostate cancer are more likely to die with their disease than of it, according to Dr Ayal Aizer from the Brigham and Women’s Hospital, the Dana-Farber Cancer Institute and Harvard University in Boston, MA — a …
ORLANDO, FLORIDA—Men over 75 were safely and effectively treated for their metastatic castration-resistant prostate cancer with the androgen receptor inhibitor enzalutamide in the Phase III AFFIRM study reported at the 2013 Genitourinary Cancers…
ORLANDO, FLORIDA—A decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients according to research presented to the 2013 Genitourinary Cancers Symposium by Dr Andrew Loblaw from the Sunnybrook Health Sciences Centre …
ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months — but have fewer side effects — according to study findings announced at the 2013 ASCO …
ORLANDO, FLORIDA—A decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients according to research presented to the 2013 Genitourinary Cancers Symposium…
ORLANDO, FLORIDA—Patients with low-risk prostate cancer are more likely to die with their disease than of it, according to Dr Ayal Aizer from the Brigham and Women’s Hospital,…
ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months…
SAN ANTONIO, TEXAS—The UK TACT2 trial, looking at over 4 000 patients with early breast cancer, has confirmed that modern chemotherapy is very effective, and continues to contribute to very high cure rates. Professor David Cameron of Edinburgh University explains …
ATLANTA, GEORGIA—A “third generation” tyrosine kinase inhibitor — ponatinib — has succeeded in controlling chronic myeloid leukaemia and Philadelphia-positive acute lymphoblastic leukaemia in patients who have the feared T 315 I mutation — which has prevented…
SAN ANTONIO, TEXAS—Women with breast cancer under the age of 35 respond very well to neo-adjuvant chemotherapy as the first line of attack against their disease, according to research from the German Breast Group presented at the 2012 San Antonio …
ATLANTA, GEORGIA—Arsenic could play a key role in perfecting gentle but curative regimens for acute promyelocytic leukaemia, according to Italian researchers reporting to the 2012 American Society of Hematology annual meeting. Professor Francesco Lo Coco…